Next report date
August 12
Report period
H1 2025
EPS estimate
—
Revenue estimate
—
−0.56 CHF
−18.64 M CHF
320.83 M CHF
13.28 M
About POLYPEPTIDE N
Sector
Industry
CEO
Juan-José Gonzalez
Website
Headquarters
Baar
Founded
1996
ISIN
CH1110760852
FIGI
BBG0100P02R8
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.
−29.5%
−22.5%
−15.5%
−8.5%
−1.5%
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
−70.00 M
0.00
70.00 M
140.00 M
210.00 M
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−70.00 M
0.00
70.00 M
140.00 M
210.00 M
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−70.00 M
0.00
70.00 M
140.00 M
210.00 M
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
−120.00 M
−60.00 M
0.00
60.00 M
120.00 M
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PPGN is 18.56 CHF — it has increased by 3.69% in the past 24 hours. Watch POLYPEPTIDE N stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange POLYPEPTIDE N stocks are traded under the ticker PPGN.
PPGN stock has fallen by −9.02% compared to the previous week, the month change is a −16.02% fall, over the last year POLYPEPTIDE N has showed a −14.07% decrease.
We've gathered analysts' opinions on POLYPEPTIDE N future price: according to them, PPGN price has a max estimate of 44.92 CHF and a min estimate of 25.45 CHF. Watch PPGN chart and read a more detailed POLYPEPTIDE N stock forecast: see what analysts think of POLYPEPTIDE N and suggest that you do with its stocks.
PPGN reached its all-time high on Sep 6, 2021 with the price of 147.40 CHF, and its all-time low was 14.12 CHF and was reached on Jan 22, 2024. View more price dynamics on PPGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PPGN stock is 5.51% volatile and has beta coefficient of 0.87. Track POLYPEPTIDE N stock price on the chart and check out the list of the most volatile stocks — is POLYPEPTIDE N there?
Today POLYPEPTIDE N has the market capitalization of 612.41 M, it has decreased by −16.22% over the last week.
Yes, you can track POLYPEPTIDE N financials in yearly and quarterly reports right on TradingView.
POLYPEPTIDE N is going to release the next earnings report on Aug 12, 2025. Keep track of upcoming events with our Earnings Calendar.
PPGN net income for the last half-year is −7.72 M CHF, while the previous report showed −10.95 M CHF of net income which accounts for 29.50% change. Track more POLYPEPTIDE N financial stats to get the full picture.
As of Mar 16, 2025, the company has 1.36 K employees. See our rating of the largest employees — is POLYPEPTIDE N on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. POLYPEPTIDE N EBITDA is 22.10 M CHF, and current EBITDA margin is 6.94%. See more stats in POLYPEPTIDE N financial statements.
Like other stocks, PPGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade POLYPEPTIDE N stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So POLYPEPTIDE N technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating POLYPEPTIDE N stock shows the sell signal. See more of POLYPEPTIDE N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.